相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The RT CHARM phase III trial demonstrated that shortened radiation therapy (3 weeks) is noninferior to conventional 5-week treatment for breast cancer patients undergoing reconstruction after mastectomy. - Complication rates were significantly lower than expected at just 14% for hypofractionated radiation and 12% for conventional radiation, with local recurrence rates remaining low at 1.5% and 2.3% respectively. - Researchers believe these findings could change the standard of care for postmastectomy radiation therapy, offering patients a more convenient treatment option without compromising reconstruction outcomes.
- A Phase 1 clinical trial of CARv3-TEAM-E T cells showed significant tumor regression in recurrent glioblastoma (GBM) patients after a single treatment. - One patient experienced near-complete tumor regression, while others showed substantial reductions in tumor size, demonstrating the therapy's potential. - The CAR-TEAM approach combines CAR-T therapy with bispecific antibodies to target both EGFRvIII and wild-type EGFR, addressing tumor heterogeneity. - While responses were observed, tumor progression eventually occurred, prompting researchers to explore strategies for extending the durability of the treatment.
